AMRX
Price
$7.80
Change
-$0.02 (-0.26%)
Updated
Aug 1, 04:23 PM (EDT)
Capitalization
1.87B
4 days until earnings call
ESPR
Price
$1.39
Change
-$0.03 (-2.11%)
Updated
Aug 1, 04:32 PM (EDT)
Capitalization
495.94M
4 days until earnings call
Interact to see
Advertisement

AMRX vs ESPR

Header iconAMRX vs ESPR Comparison
Open Charts AMRX vs ESPRBanner chart's image
Amneal Pharmaceuticals
Price$7.80
Change-$0.02 (-0.26%)
Volume$1.8K
Capitalization1.87B
Esperion Therapeutics
Price$1.39
Change-$0.03 (-2.11%)
Volume$200
Capitalization495.94M
AMRX vs ESPR Comparison Chart in %
Loading...
AMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AMRX vs. ESPR commentary
Aug 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRX is a StrongBuy and ESPR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 02, 2025
Stock price -- (AMRX: $7.82 vs. ESPR: $1.42)
Brand notoriety: AMRX and ESPR are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: AMRX: 120% vs. ESPR: 80%
Market capitalization -- AMRX: $1.87B vs. ESPR: $495.94M
AMRX [@Pharmaceuticals: Other] is valued at $1.87B. ESPR’s [@Pharmaceuticals: Other] market capitalization is $495.94M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMRX’s FA Score shows that 1 FA rating(s) are green whileESPR’s FA Score has 0 green FA rating(s).

  • AMRX’s FA Score: 1 green, 4 red.
  • ESPR’s FA Score: 0 green, 5 red.
According to our system of comparison, ESPR is a better buy in the long-term than AMRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMRX’s TA Score shows that 4 TA indicator(s) are bullish while ESPR’s TA Score has 4 bullish TA indicator(s).

  • AMRX’s TA Score: 4 bullish, 5 bearish.
  • ESPR’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ESPR is a better buy in the short-term than AMRX.

Price Growth

AMRX (@Pharmaceuticals: Other) experienced а -2.25% price change this week, while ESPR (@Pharmaceuticals: Other) price change was -4.36% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.53%. For the same industry, the average monthly price growth was +4.44%, and the average quarterly price growth was +79.95%.

Reported Earning Dates

AMRX is expected to report earnings on Nov 07, 2025.

ESPR is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-2.53% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMRX($1.87B) has a higher market cap than ESPR($496M). AMRX YTD gains are higher at: -1.263 vs. ESPR (-35.227). AMRX has higher annual earnings (EBITDA): 400M vs. ESPR (-150.11M). AMRX has more cash in the bank: 91.5M vs. ESPR (82.2M). ESPR has less debt than AMRX: ESPR (266M) vs AMRX (2.75B). AMRX has higher revenues than ESPR: AMRX (2.39B) vs ESPR (116M).
AMRXESPRAMRX / ESPR
Capitalization1.87B496M377%
EBITDA400M-150.11M-266%
Gain YTD-1.263-35.2274%
P/E Ratio90.00N/A-
Revenue2.39B116M2,064%
Total Cash91.5M82.2M111%
Total Debt2.75B266M1,034%
FUNDAMENTALS RATINGS
AMRX vs ESPR: Fundamental Ratings
AMRX
ESPR
OUTLOOK RATING
1..100
6225
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
36
Fair valued
PROFIT vs RISK RATING
1..100
62100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
5541
P/E GROWTH RATING
1..100
26100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ESPR's Valuation (36) in the Biotechnology industry is somewhat better than the same rating for AMRX (91) in the Pharmaceuticals Major industry. This means that ESPR’s stock grew somewhat faster than AMRX’s over the last 12 months.

AMRX's Profit vs Risk Rating (62) in the Pharmaceuticals Major industry is somewhat better than the same rating for ESPR (100) in the Biotechnology industry. This means that AMRX’s stock grew somewhat faster than ESPR’s over the last 12 months.

AMRX's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as ESPR (99) in the Biotechnology industry. This means that AMRX’s stock grew similarly to ESPR’s over the last 12 months.

ESPR's Price Growth Rating (41) in the Biotechnology industry is in the same range as AMRX (55) in the Pharmaceuticals Major industry. This means that ESPR’s stock grew similarly to AMRX’s over the last 12 months.

AMRX's P/E Growth Rating (26) in the Pharmaceuticals Major industry is significantly better than the same rating for ESPR (100) in the Biotechnology industry. This means that AMRX’s stock grew significantly faster than ESPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMRXESPR
RSI
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 5 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
AMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MCDCX20.61N/A
N/A
BlackRock Emerging Mkts Inv C
GQLOX34.04N/A
N/A
GMO Quality VI
IJMIX16.62N/A
N/A
VY® JPMorgan Mid Cap Value I
STPIX29.17N/A
N/A
Saratoga Technology & Comm I
CCHEX17.54N/A
N/A
Calamos Hedged Equity C

AMRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMRX has been loosely correlated with PAHC. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRX jumps, then PAHC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMRX
1D Price
Change %
AMRX100%
-3.10%
PAHC - AMRX
47%
Loosely correlated
-5.09%
HROW - AMRX
46%
Loosely correlated
-2.81%
VTRS - AMRX
43%
Loosely correlated
-2.94%
AMPH - AMRX
40%
Loosely correlated
-3.28%
ZTS - AMRX
39%
Loosely correlated
-2.03%
More

ESPR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ESPR has been loosely correlated with DVAX. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if ESPR jumps, then DVAX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESPR
1D Price
Change %
ESPR100%
+1.06%
DVAX - ESPR
33%
Loosely correlated
-1.75%
ALKS - ESPR
32%
Poorly correlated
-5.17%
AQST - ESPR
30%
Poorly correlated
-2.04%
AMPH - ESPR
29%
Poorly correlated
-3.28%
AMRX - ESPR
28%
Poorly correlated
-3.10%
More